Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Reiterates Outperform Rating on Biogen (BIIB)
May 14, 2026 8:17 AM EDTMizuho analyst Salim Syed reiterated an Outperform rating and $236.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "This morning, Biogen announced topline results from its Ph2 trial (CELIA) for BIIB080 (tau ASO) in early Alzheimer's Disease. The study technically failed to meet the primary endpoint (CDR-SB at 76 weeks). The interesting piece here though is Biogen is moving the program forward "based on the strength of the... More
Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'
May 14, 2026 7:44 AM EDTWolfe Research analyst Alexandria Hammond reiterated a Peerperform rating and {REMOVEPT} price target on Biogen (NASDAQ: BIIB).
The analyst comments "Biogen's (BIIB) tau-targeting ASO, diranersen, misses on primary endpoint. Today, BIIB announced phase 2 results from its 18-month, CELIA study, which was a placebo-controlled trial evaluating diranersen (formerly BIIB080) in patients with early Alzheimer's disease. Recall, diranersen is an antisense oligonucleotide (ASO) therapy targeting intracellular tau, which differentiates it from prior anti-tau therapies. CELIA failed to meet its primary endpoint assessing dose response at week 76 on the Clinical Dementia RatingSum of Boxes (CDR-SB) as... More
Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'
May 14, 2026 7:29 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $214.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "Biogen announced this morning that the BIIB080 (Alzheimer's) study did not meet its primary endpoint, which was assessing the dose response on clinical efficacy. They're still advancing the program though, and in our view, we don't think the "bar" to advance the program was low (this is an intrathecal drug, and, under CEO Chris Viehbacher, Biogen has pared back their investments in risky CNS R&D projects). We caught up with Biogen briefly--they aren't... More
